ClinicalTrials.gg
RecruitingNCT07730827Updated Jul 28, 2026

Community-Informed Interventions for Equitable Congestive Heart Failure Management in Primary Care

An observational study in Congestive Heart Failure and Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.

Planned enrollment
8th of 18
75 · median 63
Started
2026
with 4 others
Observational
21 of 69
6 open now
Primary completion
2028-07
later than 14 of 16 live
Registered
69th of 69
by date

Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2026, is one of 21 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 69th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Failure by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to expand subject matter expertise and sustained capacity for equity-oriented care within the Advanced Care Ecosystem (ACE) by engaging patients, caregivers, community health workers (CHW), and care-team stakeholders in development work focused on adults living with congestive heart failure (CHF) and adverse social determinants of health (SDoH).

03

Conditions studied

  • Congestive Heart Failure
  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adults with congestive heart failure (CHF) who receive primary care at Mayo Clinic in Rochester and have evidence of adverse social determinants of health, elevated health care utilization, or other medical or social complexity relevant to CHF self-care and transitions-of-care support. Eligible patients may nominate adult caregivers or family members to participate when their perspective is relevant to the patient's CHF care experience. The study will also include adult Community Health Workers, chronic disease nurse care coordinators, education specialists, clinicians, and other clinical or operational stakeholders with roles relevant to CHF care, transitions of care, social needs, patient education, or CHW workflows.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients living with congestive heart failure (CHF):

  • Age 18 years or older.
  • Diagnosis or clinical documentation of CHF or heart failure in the Mayo Clinic medical record.
  • Empaneled in Mayo Clinic, Rochester, primary care
  • Evidence in the EHR of one or more adverse SDoH, elevated utilization, medical/social complexity.
  • Able to provide .
  • Able to participate in study procedures.

Caregivers:

  • Age 18 years or older.
  • Caregiver with relevant lived, caregiving, or community experience related to CHF, and nominated by the patient.
  • Able to provide informed consent
  • Able to participate in study procedures.

Community health worker and care-team stakeholders:

  • Age 18 years or older.
  • Current or recent role relevant to CHF care, transitions of care, SDoH, patient education, or CHW workflows.
  • Able to provide informed consent
  • Able to participate in study procedures.

Exclusion criteria

Exclusion Criteria:

  • Under age 18 years.
  • Unable or unwilling to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults living with congestive heart failure (CHF)

    Adults living with CHF receiving primary care at Mayo Clinic Rochester with adverse SDoH, elevated utilization, or related medical/social complexity

    Other: Interviews and group discussion for patients and caregivers

  • Caregivers or family members of eligible congestive heart failure (CHF) patients

    Caregivers or family members of eligible CHF patients nominated by the patient

    Other: Interviews and group discussion for patients and caregivers

  • Community health workers and care-team stakeholders

    Community health workers, chronic disease RN care coordinators, education specialists, clinicians, and operational leaders

    Other: Interviews and group discussion for community health worker and care-team stakeholders

Interventions

  • OtherInterviews and group discussion for patients and caregivers

    Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes, conducted in person, by telephone, or by Mayo-approved video platform. Interview and discussion guides will include discussion of barriers, facilitators, preferences, priorities, and care gaps related to congestive heart failure self-care, access, transitions of care, community health worker support, caregiver support, social needs, health literacy, language access, trust, and culturally responsive care.

  • OtherInterviews and group discussion for community health worker and care-team stakeholders

    Participants will be asked to complete an individual interview or participate in a group discussion lasting approximately 60 to 120 minutes. Interview and discussion guides will focus on development of a community health worker competency-based training module and development of workflows for community health workers to support congestive heart failure patients' self-management and care transitions. Participants will provide feedback on implementation barriers and facilitators, including training burden, role clarity, sustainability, cultural responsiveness, and integration with clinical care teams.

06

What researchers measure

Primary outcomes

  1. Identification of prioritized barriers to self-care

    Total number of prioritized barriers to equitable congestive heart failure self-care and transitions-of-care support identified through participant interviews and group discussions.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 24 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730827
Lead sponsor
Mayo Clinic
Responsible party
Majken Wingo (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jul 28, 2026
Start date
Jul 6, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Amber Woltzen
Contact
woltzen.amber@mayo.edu
507-422-6732
Majken T. Wingo, MD
principal investigator · Mayo Clinic
Jane W. Njeru, MB, ChB
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion